🇰🇷 Blincyto in South Korea

Blincyto (blinatumomab) regulatory status in South Korea.

Marketing authorisation

MFDS

  • Status: likely_approved

Blincyto in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in South Korea

Frequently asked questions

Is Blincyto approved in South Korea?

Yes. MFDS has authorised it.

Who is the marketing authorisation holder for Blincyto in South Korea?

Amgen is the originator. The local marketing authorisation holder may differ — check the official source linked above.